GlassScriptPhysician profile
Harshadkumar C Patel
NPI 1952568008
$6,234.04
in general payments reported to CMS, 2019-2025
32 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $282 · 2021: $223 · 2022: $625 · 2023: $985 · 2024: $1,725 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,284.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,147.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $713.30 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $572.44 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $520.60 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $389.99 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $311.67 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $244.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $230.99 | 2019-2025 | Invega, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $220.51 | 2024-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $190.85 | 2025 | Cobenfy |
| Lundbeck LLC | $190.51 | 2019-2025 | Rexulti |
| Tris Pharma INC | $184.04 | 2019-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $183.98 | 2024-2025 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.32 | 2023-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $156.23 | 2024-2025 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $116.54 | 2023-2025 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $116.36 | 2023 | Quviviq |
| Bausch Health US, LLC | $92.80 | 2019-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $76.18 | 2024-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $61.92 | 2024 | |
| Harmony Biosciences LLC | $50.00 | 2020 | |
| Shire North American Group INC | $46.37 | 2019 | |
| Vanda Pharmaceuticals INC. | $37.68 | 2024 | Hetlioz, Fanapt |
| Allergan, INC. | $35.52 | 2019 | |
| Collegium Pharmaceutical, INC. | $33.89 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $30.31 | 2019-2022 | |
| Sage Therapeutics, LLC | $27.64 | 2025 | Zurzuvae |
| Corium, LLC | $21.93 | 2023 | Azstarys |
| Janssen Biotech, INC. | $20.55 | 2022 | |
| Avion Pharmaceuticals | $14.90 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $14.20 | 2024 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshadkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.